GLP-1 Drug Discovery Success Transformed Pharmaceutical R&D
From gut hormones to global therapeutics, GLP-1 drug discovery transformed obesity treatment through peptide engineering and incretin biology translation.
FDA Generic Peptides Guidance Sets New Expectations
Revised FDA draft guidance for generic peptide products updates expectations for ANDAs, impurities, structure, immune response, and biological activity.
GLP-1 Obesity Evidence Is Changing Clinical Development
GLP-1 obesity clinical evidence is reshaping drug development as efficacy, safety, cardiovascular outcomes, and treatment durability become critical.
Bioprocessing Is Becoming a Smarter Manufacturing System
Bioprocessing is becoming more connected, automated, and data-driven. Here is what smarter process control means for biopharma manufacturing.
CRO Data Quality: Why Sponsor Datasets Slow MIDD
CRO data quality decides how fast MIDD models reach regulators. See what a pharmacometric CRO survey reveals about sponsor data, costs, and AI-led fixes.
Could Biological Ageing Be the Next Big Shift in Drug Discovery?
“The pharma industry is beginning to look at biological age as a surrogate endpoint to improve clinical trials."